Semiconductor supply chain risk is no longer a background concern for medical device makers, it is a direct line to production stoppages. Advanced imaging systems, implantable monitors, and diagnostic platforms depend on chips from a small number of facilities in Taiwan and South Korea, and that concentration is the single biggest geographic exposure most device manufacturers carry today.
The short answer: if a Taiwan Strait disruption or export restriction interrupts chip supply from TSMC, most medical device OEMs have no viable second source for their most advanced components. That is the structure of the market as it exists right now, not a hypothetical.
Why one region controls the components your devices depend on
Taiwan hosts more than 70 percent of global logic advanced packaging capacity, while South Korea holds roughly 85 percent of high-bandwidth-memory advanced packaging, according to McKinsey’s analysis of the semiconductor supply chain. The United States accounts for around 1 percent of global logic advanced packaging and effectively none of high-bandwidth-memory packaging.
For a device maker, that geography maps directly onto production risk. Imaging systems, implantable cardiac monitors, and diagnostic equipment are heavy consumers of the most advanced chip nodes, concentrated almost entirely in Taiwan. Research on the Taiwan semiconductor fault line notes that TSMC alone produces the overwhelming majority of the world’s most advanced chips below 5nm, with no comparable alternative foundry able to absorb that volume on short notice.
This is a sub-tier visibility problem as much as a geopolitical one. A tier-1 contract manufacturer can look financially healthy and fully stocked while the tier-2 or tier-3 chip supplier behind it sits entirely inside a single strait or a single set of export control rules.
What happens when the chip layer breaks
Procurement teams do not need a blockade scenario to feel this. Smaller shocks already show up on the FDA’s Medical Device Shortages List, which currently tracks devices including oxygenators, stereotactic breast biopsy needles, and endoscopic vessel harvesting systems, several with shortage durations now stretching into 2027.
McKinsey has separately estimated that a serious disruption to Taiwan’s chip output could cause on the order of $2 trillion to $3 trillion in annual global economic damage. A device maker does not need the full-scale version of that event to feel it: a partial export restriction, a fab outage, or a shipping bottleneck through a contested strait is enough to stall a line that depends on a single-source chip package.
Quarterly supplier reviews cannot catch this kind of exposure. By the time a risk report reaches a CPO’s desk, the chip allocation decision was made months earlier, at a tier of the supply chain the device OEM never directly audits.
What good looks like: continuous, dollar-quantified visibility
The alternative is not diversifying away from Taiwan overnight. Advanced packaging capacity does not relocate on a procurement team’s timeline. The real alternative is knowing, in dollar terms, how much working capital and production volume sits behind a single geographic chokepoint, and updating that number continuously rather than once a quarter.
Chain Verity was built for this gap. Instead of a static, traffic-light score, Chain Verity tracks 200-plus real-time financial and operational signals across tier 1, 2, and 3 suppliers and expresses exposure as actual dollars of working capital at risk, not a color code. That gives medical device procurement teams a way to see concentration risk building before it becomes a shortage entry on a regulator’s list. Explore how continuous monitoring works, or join the current design partner group.
Semiconductor concentration is not going away this year or next. What can change is how early a procurement organization sees it coming.
Frequently Asked Questions
Q: Why is semiconductor supply concentration such a big risk for medical device makers specifically?
A: Advanced imaging, implantable monitors, and diagnostic devices rely on chip nodes that are overwhelmingly produced in Taiwan, with South Korea dominating high-bandwidth-memory packaging. There is no comparable alternative foundry at scale, so a disruption in either location has an outsized effect on device production compared to industries with more geographically distributed component sourcing.
Q: What is currently on the FDA’s Medical Device Shortages List?
A: As of mid-2026, the list includes items such as oxygenator devices, stereotactic breast biopsy needles, endoscopic vessel harvesting systems, and neurosurgical patties, sponges, and strips, with several shortages expected to extend into 2027. Details are updated directly on the FDA’s shortage list page.
Q: Can procurement teams realistically diversify away from Taiwan-based chip suppliers?
A: Not quickly. Advanced packaging capacity is capital-intensive and geographically fixed in the near term, so full diversification is a multi-year undertaking. The more immediate lever is visibility: knowing the dollar exposure sitting behind a single-source chip supplier so a disruption is a managed event rather than a surprise.
Q: How is this different from a standard supplier risk score?
A: A traffic-light score tells a procurement leader that a supplier is “yellow” without saying how many dollars of production or working capital are actually exposed. Continuous, quantified monitoring across tier 1, 2, and 3 suppliers closes that gap by attaching a real number to the risk, updated as conditions change rather than on a quarterly cycle.
